SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) experienced extreme volatility, surging thousands of percentage points following news of a significant crypto treasury investment, leading to a frenzy among day traders and short sellers. The community is actively debating whether the massive gains are sustainable, with many pointing to potential dilution and insider selling, while others anticipate a continued squeeze. Speculation is high as traders look for the next stock to replicate $OCTO's meteoric rise, leading to increased attention on other low-float and crypto-related stocks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following a multi-billion dollar agreement with Microsoft to provide AI infrastructure, fueling excitement around the company's growth potential in the AI cloud sector. The community is buzzing about the size and impact of the deal, with some suggesting it could lead to significant revenue growth and new all-time highs. Some analysts see the stock as undervalued given the broader context of increased AI infrastructure spending.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending due to a live demonstration of its solid-state batteries powering a Ducati motorcycle, showcasing faster charging and higher energy density which has sparked optimism about the technology's potential and real-world application. The community is discussing the implications of this milestone, including potential partnerships with major automakers and the possibility of a short squeeze. However, some are cautious, pointing to the long timeline for commercial production and past disappointments.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to a proposed $300M private offering of convertible senior notes, announced after a positive earnings call, leading to concerns about dilution and prompting community discussion around the timing and necessity of the offering. While some investors see it as a strategic move for long-term growth and warrant management, others view it as a deceptive practice that takes advantage of retail investors after a strong earnings report. The community is actively debating the implications of the offering, including conversion prices, capped call strikes, and potential impact on share value and future growth prospects.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Sentage Holdings Inc is trending due to speculative interest, drawing comparisons to recent high-flying low floaters like $OCTO and $MGIH. Community chatter suggests anticipation for a potential short squeeze and after-hours momentum. Some traders are also noting the stock's low float and potential for significant price movement, while others caution about its fundamentals.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending amidst growing speculation about its spectrum value, particularly after SpaceX's recent spectrum acquisition, and ahead of a potential Apple event where satellite integration could be a talking point. Community discussions revolve around potential bidding wars for Globalstar's spectrum and the company's improving financials. Bullish sentiment is fueled by hopes for new contracts and partnerships, especially with major players like Walmart and government entities, and the potential impact of the new satellite constellation.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

CASY is trending as investors discuss the potential impact of upcoming earnings on the stock's trajectory, with community members debating whether it will be a bull trap or a sustained rally. The stock's valuation and recent performance are key points of contention, as some question whether it is overvalued, while others highlight its growth potential and dividend increases. Community members are also sharing information regarding recent news, analyst ratings, and historical performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid community discussions around the release of documents related to Jeffrey Epstein and their potential implications for prominent figures, including Donald Trump. Sentiment appears divided, with some users expressing concern and others dismissing the relevance of the news. The stock's movement is also being attributed to broader market trends and upcoming economic data.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as traders discuss a potential breakout, fueled by recent earnings and revenue numbers despite some ongoing concerns around profitability. The community is weighing the impact of expiring warrants and speculating about potential catalysts, including a short squeeze. Some are drawing comparisons to other insurance companies and the company's relatively low market cap.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics (MCRB) is trending amid speculation of a potential acquisition offer from Nestle, with reports circulating in Swiss media, although there is no official confirmation yet. The community is actively discussing the likelihood of a deal, potential offer prices, and what it could mean for current shareholders, and some speculate that a merger is more likely. Discussions also revolve around the potential for a short squeeze, given the stock's high short interest and low float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy

Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.

Arrowhead Pharmaceuticals, Inc. (ARWR) on Tuesday announced a global licensing and collaboration agreement with Swiss pharmaceutical giant Novartis (NVS) for its investigational therapy for the treatment of neurodegenerative disorders such as Parkinson’s Disease.Under the agreement, Novartis will receive an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA, a preclinical-stage program for the potential treatment of patients with Parkinson’s disease and other synucleinopathies. Novartis will also select additional collaboration targets outside of Arrowhead’s current pipeline to be developed using Arrowhead’s Targeted RNAi Molecule (TRiM) platform, Arrowhead said.Meanwhile, Arrowhead will <a target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-and-novartis-enter-into-a-global-license-and-collaboration-agreement/">receive</a> a $200 million upfront payment and is eligible to receive up to $2 billion in potential milestone payments, in addition to royalties on commercial sales.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> rose by 11% at the time of writing, while NVS stock traded marginally in the red. On Stocktwits, retail sentiment around ARWR stayed within ‘bearish’ territory over the past 24 hours, while message volume rose to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_9_57_14_AM_png_dadf30ac72.webp" alt="ARWR's Sentiment Meter and Message Volume as of 9:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>ARWR's Sentiment Meter and Message Volume as of 9:57 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_10_00_31_AM_png_703e9e6f44.webp" alt="NVS's Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="574" height="60"><figcaption>NVS's Sentiment Meter and Message Volume as of 10:00 a.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes that Arrowhead getting $200 million upfront for a pre-clinical asset is a “hell of a deal.”<stembedurl>https://stocktwits.com/Pika_Capital/message/627215281</stembedurl>Arrowhead will conduct and complete the necessary preclinical research activities to enable the filing of a clinical trial application for all licensed programs under the agreement. Novartis will then assume sole control over development, manufacturing, medical affairs, and commercialization activities. The transaction is expected to close in the second half of 2025.CEO Christopher Anzalone stated that the company looks forward to beginning clinical trials for ARO-SNCA “as soon as possible.” Both ARWR stock and NVS stock is up by about 30% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-stock-tanks-after-cancer-drug-candidate-update/chv6sI8Rdny">Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’

Under the agreement, Arrowhead will receive a $200 million upfront payment and is eligible to receive up to $2 billion in potential milestone payments, as well as royalties on commercial sales.

Equity

H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its credibility in capital allocation.The firm also highlighted concerns that Sarepta's late-stage and commercial portfolio may not generate sufficient near-term cash to support its current debt and pipeline ambitions.H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. The brokerage noted that <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> fully unwound its equity position in Arrowhead less than a year after investing $325 million in the stock. The unwinding represented a 31% decline as compared to the purchase price, it added.On Stocktwits, retail sentiment around the stock trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Retail chatter around the stock jumped 131% over the past 24 hours, as of Thursday morning.<figure class="image"><img style="aspect-ratio:625/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_11_12_15_AM_png_aaca6c7ce4.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits" width="625" height="58"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:10 a.m. ET on Aug. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Sarepta selling its investment in Arrowhead.<stembedurl>https://stocktwits.com/Zergg/message/625149352</stembedurl>Another user hopes the stock will hit $30 by next week.<stembedurl>https://stocktwits.com/markxtill/message/625143002</stembedurl>Sarepta on Wednesday <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-keeps-retail-traders-bullish-as-stock-surges-on-100-m-milestone-payment-to-arrowhead-in-genetic-disorder-trial/chsR9ZARdak">said</a> that it sold about 9.27 million shares of common stock of Arrowhead in a privately negotiated block trade from which it expects to receive at least $174 million in gross proceeds.The company also said that it has entered into an agreement with Arrowhead under which it will transfer over 2.66 million shares of <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> back to the company to satisfy a $50 commitment of a $100 milestone payment obligation. The remaining $50 million will be received in cash, Arrowhead said. Sarepta previously owned 11.93 million shares of Arrowhead stock.Sarepta’s gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure. Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.However, SRPT stock is down by 84% this year and by 85% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hertz-expands-program-allowing-prolonged-3-day-test-drives-before-vehicle-purchase-to-over-100-cities/chsRlcNRdOh">Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Sarepta Sells Arrowhead Stake to Fund Milestone Payment

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review and enrollment progress in its Phase 1/2 trial of SRP-1003 for type 1 myotonic dystrophy (DM1) triggered a $100 million milestone payment to Arrowhead Pharmaceuticals.<a href="https://stocktwits.com/symbol/SRPT">Sarepta’s stock</a> jumped 8.5% to close at $20.4 on Wednesday, with an additional 1.6% gain in after-hours trading.The payment was triggered after Arrowhead reached the first of two predetermined enrollment targets in the study, following a review of the safety data.&nbsp;SRP-1003 is an experimental RNA interference therapy being developed for type 1 myotonic dystrophy.To help fund the milestone payment, Sarepta sold 9.3 million shares of Arrowhead in a privately negotiated block trade, generating at least $174 million in gross proceeds.&nbsp;Arrowhead will also redeem 2.7 million shares from Sarepta for $50 million, prefunding half of the milestone obligation.The company plans to share early results from the SRP-1003 trial and its facioscapulohumeral muscular dystrophy (FSHD) program in the second half of 2025.On Stocktwits, retail sentiment was ‘bullish’ for Sarepta Therapeutics and ‘extremely bullish’ for Arrowhead Pharmaceuticals, with 24-hour message volumes surging 872% and 122%, respectively.One user remarked that upgrades for Sarepta Therapeutics keep coming, adding that the market may be underestimating how quickly sentiment can shift when major investors get involved.&nbsp;<stembedurl>https://stocktwits.com/BookerB/message/625098239</stembedurl>Another said the stock could still rise tenfold within a year if European approval comes through and with multiple trials underway, calling it a bargain and urging others to buy before the current discount disappears.<stembedurl>https://stocktwits.com/Mejeko/message/625096804</stembedurl>While Sarepta’s stock has declined 83.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/ARWR">Arrowhead’s stock</a> gained 6.3% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Sarepta to Report Q2 Earnings: What's in Store for the Stock?

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

Arrowhead Pharmaceuticals, Inc. (ARWR) announced on Wednesday that it expects its licensing partner, Sarepta Therapeutics (SRPT), to continue meeting its required financial obligations to the company despite recent setbacks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARWR">Arrowhead</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_11_32_10_AM_png_db10f4a9a5.webp" alt="ARWR's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits" width="624" height="61"><figcaption>ARWR's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits</figcaption></figure>Retail chatter around Arrowhead increased by 83% over the past seven days.Arrowhead has an ongoing exclusive license and collaboration agreement with <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a>, including four clinical-stage drug candidates and three pre-clinical programs.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250723517597/en/Arrowhead-Pharmaceuticals-Issues-Statement-on-the-Status-of-its-Ongoing-Agreement-with-Sarepta-Therapeutics">stated</a> on Wednesday that it continues to conduct clinical and non-clinical studies as stipulated in the agreement and that Sarepta has provided no indication of any intention to fail to fulfill its obligations. Furthermore, Sarepta has experienced setbacks in products and programs unrelated to those licensed from Arrowhead, the company noted.However, if Sarepta fails to meet its financial obligations, there are clear termination provisions that would cause assets and associated intellectual property to be returned to Arrowhead, the company stated. Arrowhead would further have no obligation to return any consideration Sarepta had already paid, it noted.Upon closing the agreement with Sarepta in February, Arrowhead received a $500 million upfront payment and an additional $325 million through Sarepta's purchase of Arrowhead common stock. As per the terms of the agreement, Arrowhead will also receive $250 million, payable in annual installments of $50 million over five years, and is eligible to receive $300 million in near-term payments associated with certain milestones.Arrowhead believes it is on track to earn the first $100 million soon and the remaining $200 million by year-end.A Stocktwits user applauded the “tone and positioning” of Arrowhead’s announcement.<stembedurl>https://stocktwits.com/johnnygogogo/message/622060994</stembedurl>Earlier this week, Sarepta <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-pauses-elevidys-shipments-amid-fda-label-review/ch8MbFbR5rD">announced a voluntary halt</a> to U.S. shipments of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.On Stocktwits, retail sentiment around Sarepta trended in the ‘extremely bullish’ territory, coupled with ‘extremely high’ message volume. The message count around Sarepta has surged 595% over the past seven days.<figure class="image"><img style="aspect-ratio:626/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_23_at_11_30_36_AM_png_2a121005a7.webp" alt="SRPT's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits" width="626" height="60"><figcaption>SRPT's Sentiment Meter and Message Volume as of 11:30 a.m. ET on July 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for Sarepta’s Elevidys to be reintroduced to the market.<stembedurl>https://stocktwits.com/Newcar/message/622087250</stembedurl>At the time of writing, ARWR stock was trading 11% higher, while SRPT stock had risen by 2%.SRPT stock, however, has fallen by about 89% this year.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-collaborates-with-four-critical-mineral-producers-to-strengthen-supply-chain/ch8wsttR5MC">Lucid Collaborates With 4 Critical Mineral Producers To Strengthen Supply Chain: Retail Deems It A ‘Comeback’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement

Arrowhead believes it is on track to earn the first $100 million soon and the remaining $200 million by the end of the year under its agreement with Sarepta. 

SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut 

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARWR News

ARWR Arrowhead Pharmaceuticals Inc.